flanders.bio is an independent life sciences cluster organisation based in Flanders, Belgium

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

ERS Genomics and Syngulon Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications

ERS Genomics Ltd and Syngulon, a synthetic biology startup developing original genetic technologies using bacteriocins, announced today a non-exclusive license agreement which provides Syngulon with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in combination with Syngulon Patent Rights. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.

Convert Pharmaceuticals appoints Mariola Söhngen as new CEO

Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, announces that Dr Mariola Söhngen joined as CEO, as the company gears up for its first-in-human clinical trials with its lead program.

People | 08 November 18 Read more

Novosanis Colli-Pee approved by Mexican health authority

Novosanis, an innovative developer and producer of medical devices, announced today that Colli-Pee, a user-friendly self-sampling device suited for standardized collection of first-void or first-catch urine has been approved by COFEPRIS, the Federal Commission for the Protection against Sanitary Risk in Mexico.

MDxHealth (R): SelectMDx improves prostate biopsy decision-making in urology practices

MDxHealth SA (Euronext: MDXH.BR) or the "Company" today announces that the journal Urology Practice has published a study demonstrating the clinical utility of SelectMDx, the Company's non-invasive 'liquid biopsy' test to identify patients at increased risk of aggressive prostate cancer, in guiding initial prostate biopsy decision-making.

flanders.bio events, trainings & international missions

Strategic Partners